Ganirelix

Subcutaneous
Ovarian stimulation regimens for assisted reproduction in infertility

Moderate to severe: Contraindicated.

Moderate to severe: Contraindicated.

Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue. Moderate to severe renal or hepatic impairment. Pregnancy and lactation.

Women w/ signs and symptoms of active allergic conditions.

Hypersensitivity reactions including anaphylactoid reactions, headache, nausea, GI abdominal pain, neutrophil count ≥8.3/mm³, gynaecologic abdominal pain, ovarian hyperstimulation syndrome, vag bleeding, inj site reactions, foetal death.

Parenteral/SC: X

Perform ultrasound to assess follicle size.

May require dose adjustment of exogenous gonadotropins when concomitantly used during controlled ovarian hyperstimulation.

Description: Ganirelix competitively blocks the gonadotrophin-release hormone receptors on the pituitary gonadotroph and transduction pathway, resulting to a rapid, reversible suppression of gonadotrophin and luteinising hormone secretion, thus preventing ovulation until the follicles are of adequate size.
Duration: <48 hr.
Pharmacokinetics:
Absorption: Rapidly absorbed. Bioavailability: Approx 91%. Time to peak plasma concentration: 1.1 hr.
Distribution: Volume of distribution: 43.7 L. Plasma protein binding: 81.9%.
Metabolism: Metabolised via enzymatic hydrolysis to 2 primary metabolites (1-4 and 1-6 peptide).
Excretion: Via faeces (approx 75% as metabolites); urine (approx 22% as unchanged drug). Elimination half-life: Approx 13 hr.

Source: National Center for Biotechnology Information. PubChem Database. Ganirelix, CID=16130957, https://pubchem.ncbi.nlm.nih.gov/compound/Ganirelix (accessed on Jan. 22, 2020)

Store at 25°C. Protect from light.

Trophic Hormones & Related Synthetic Drugs

H01CC01 - ganirelix ; Belongs to the class of anti-gonadotropin-releasing hormones. Used in hypothalamic hormone preparations.

Anon. Ganirelix. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/12/2015.

Buckingham R (ed). Ganirelix acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/12/2015.

Ganirelix acetate Injection, Solution (Organon USA Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/12/2015.

Ganirelix acetate Injection. U.S. FDA. https://www.fda.gov/. Accessed 03/12/2015.

Joint Formulary Committee. Ganirelix. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/12/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Ganirelix acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/12/2015.